drugset / Trial / NCT06345404
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
RandomizedSequentialQuadruple-blindTreatment
Summary
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Timeline
- Start
- 2024-04-16
- Primary completion
- 2026-01-28
- Completion
- 2026-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Soquelitinib | Small molecule | 100 mg | Oral |
| Subject | Soquelitinib | Small molecule | 200 mg | Oral |